Wells Fargo & Company Glycomimetics Inc Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLYC
# of Institutions
81Shares Held
36.8MCall Options Held
969KPut Options Held
636K-
Bvf Inc San Francisco, CA9.54MShares$2.58 Million0.86% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$2.32 Million1.39% of portfolio
-
Nea Management Company, LLC Timonium, MD3.84MShares$1.04 Million0.81% of portfolio
-
Octagon Capital Advisors LP New York, NY3MShares$810,0001.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$745,7340.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $14.2M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...